# US 2024/0200079 A1 · Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200079 A1
- Document ID: US20240200079A1
- Status: Published application
- Kind: A1
- Application number: 18/392,181
- Filed: 2023-12-21
- Published: 2024-06-20
- Earliest claimed: 2021-08-07
- Assignees: Regeneron Pharmaceuticals, Inc.; The Royal Institution for the Advancement of Learning/Mcgill University
- Applicants: Regeneron Pharmaceuticals, Inc.; The Royal Institution for the Advancement of Learning / McGill University
- Inventors: Jonas Bovijn; Olukayode Sosina; Sirui Zhou; Luca Andrea Lotta; Aris Baras; John Brent Richards
- Web page: https://patentgrep.com/patent/US20240200079A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/23: Calcitonins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/30: Special therapeutic applications
- C12Q 2600/156: Polymorphic or mutational markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

## Claims

### Claim 1

A method of treating a subject having decreased bone mineral density, an osteopenia, Type I osteoporosis, Type II osteoporosis, or secondary osteoporosis or at risk of developing decreased bone mineral density, an osteopenia, Type I osteoporosis, Type II osteoporosis, or secondary osteoporosis the method comprising administering a Cluster of Differentiation 109 (CD109) inhibitor to the subject.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the CD109 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a CD109 nucleic acid molecule.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).

### Claim at position 5

8-13. (canceled)

### Claim 14 (depends on 1)

The method according to claim 1, further comprising detecting the presence or absence of a CD109 missense variant nucleic acid molecule encoding a CD109 predicted loss-of-function polypeptide in a biological sample from the subject.

### Claim 15 (depends on 14)

The method according to claim 14, further comprising administering a therapeutic agent that treats or inhibits decreased bone mineral density in a standard dosage amount to a subject wherein the CD109 missense variant nucleic acid molecule is absent from the biological sample.

### Claim 16 (depends on 14)

The method according to claim 14, further comprising administering a therapeutic agent that treats or inhibits decreased bone mineral density in a dosage amount that is the same as or less than a standard dosage amount to a subject that is heterozygous for the CD109 missense variant nucleic acid molecule.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the CD109 predicted missense variant nucleic acid molecule is a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated CD109 predicted loss-of-function polypeptide.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the CD109 predicted loss-of-function variant nucleic acid molecule is 6:73730573:A:G, 6:73823473:GA:G, 6:73763607:C:A, 6:73803256:G:T, 6:73818486:T:C, 6:73787379:G:A, 6:73771510:A:G, 6:73806987:A:T, 6:73758991:A:G, 6:73823456:A:G 6:73762778:A:C, 6:73763660:A:G, 6:73730573:A:G, 6:73806956:G:A, 6:73792628:G:C, 6:73806926:A:T, 6:73771576:G:A, 6:73815026:C:T, 6:73765952:G:A, or an mRNA molecule produced therefrom, or a cDNA molecule produced from the mRNA molecule.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the CD109 missense variant nucleic acid molecule encodes a truncated CD109 predicted loss-of-function polypeptide.

### Claim 20

A method of treating a subject with a therapeutic agent that treats or inhibits decreased bone mineral density, wherein the subject has decreased bone mineral density or is at risk of developing decreased bone mineral density, the method comprising the steps of:
determining whether the subject has a Cluster of Differentiation 109 (CD109) missense variant nucleic acid molecule encoding a CD109 predicted loss-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CD109 missense variant nucleic acid molecule; and
administering or continuing to administer the therapeutic agent that treats or inhibits decreased bone mineral density in a standard dosage amount to a subject that is CD109 reference, and/or administering a CD109 inhibitor to the subject;
administering or continuing to administer the therapeutic agent that treats or inhibits decreased bone mineral density in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous for the CD109 missense variant nucleic acid molecule, and/or administering a CD109 inhibitor to the subject; or
administering or continuing to administer the therapeutic agent that treats or inhibits decreased bone mineral density in an amount that is the same as or less than a standard dosage amount to a subject that is homozygous for the CD109 missense variant nucleic acid molecule;
wherein the presence of a genotype having the CD109 missense variant nucleic acid molecule encoding the CD109 predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing decreased bone mineral density.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the subject is CD109 reference, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits decreased bone mineral density in a standard dosage amount, and is administered a CD109 inhibitor.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the subject is heterozygous for a CD109 missense variant nucleic acid molecule, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits decreased bone mineral density in an amount that is the same as or less than a standard dosage amount, and is administered a CD109 inhibitor.

### Claim 23 (depends on 20)

The method according to claim 20, wherein the CD109 missense variant nucleic acid molecule is a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated CD109 predicted loss-of-function polypeptide.

### Claim 24 (depends on 20)

The method according to claim 20, wherein the CD109 predicted loss-of-function variant nucleic acid molecule is 6:73730573:A:G, 6:73823473:GA:G, 6:73763607:C:A, 6:73803256:G:T, 6:73818486:T:C, 6:73787379:G:A, 6:73771510:A:G, 6:73806987:A:T, 6:73758991:A:G, 6:73823456:A:G 6:73762778:A:C, 6:73763660:A:G, 6:73730573:A:G, 6:73806956:G:A, 6:73792628:G:C, 6:73806926:A:T, 6:73771576:G:A, 6:73815026:C:T, 6:73765952:G:A, or an mRNA molecule produced therefrom, or a cDNA molecule produced from the mRNA molecule.

### Claim 25 (depends on 20)

The method according to claim 20, wherein the CD109 missense variant nucleic acid molecule encodes a truncated CD109 predicted loss-of-function polypeptide.

### Claim 26 (depends on 20)

The method according to claim 20, wherein the CD109 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a CD109 nucleic acid molecule.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).

### Claim at position 20

28-33. (canceled)

### Claim 34 (depends on 20)

The method according to claim 20, wherein the decreased bone mineral density is an osteopenia, Type I osteoporosis, Type II osteoporosis, or secondary osteoporosis.

### Claim at position 22

35-37. (canceled)

### Claim 38 (depends on 20)

The method according to claim 20, wherein the therapeutic agent is chosen from alendronate, ibandronate, zoledronate, risedronate, calcitonin, teriparatide, denosumab, estrogen and progesterone, raloxifene, or any combination thereof.

### Claim at position 24

39-78. (canceled)
